ARS Pharmaceuticals, Inc (SPRY) — Financial Flexibility Index
ARS Pharmaceuticals, Inc (SPRY) has a Financial Flexibility Index of -0.20x as of December 2025. Free cash flow of $-43.48 Million (operating CF $-43.48 Million minus capex $0.00) represents 0% of total liabilities ($213.39 Million). Check SPRY capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
ARS Pharmaceuticals, Inc Financial Flexibility Index (2018–2025)
Historical Financial Flexibility Index trend for ARS Pharmaceuticals, Inc across 8 annual periods. See ARS Pharmaceuticals, Inc (SPRY) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for ARS Pharmaceuticals, Inc (2018–2025)
Year-by-year free cash flow to debt coverage for ARS Pharmaceuticals, Inc. For the full company profile including market capitalisation, see SPRY stock market capitalisation.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.80x | $-170.53 Million | $-170.87 Million | $213.39 Million | ▼ -634.3% |
| 2024 | 0.15x | $14.11 Million | $13.55 Million | $94.36 Million | ▲ +100.6% |
| 2023 | -24.34x | $-59.09 Million | $-59.27 Million | $2.43 Million | ▼ -421.7% |
| 2022 | -4.66x | $-39.88 Million | $-40.08 Million | $8.55 Million | ▼ -2370.5% |
| 2021 | -0.19x | $-17.51 Million | $-17.56 Million | $92.72 Million | ▼ -176.5% |
| 2020 | 0.25x | $9.99 Million | $9.07 Million | $40.46 Million | ▲ +127.9% |
| 2019 | -0.88x | $-18.80 Million | $-18.90 Million | $21.25 Million | ▲ +49.6% |
| 2018 | -1.76x | $-16.43 Million | $-16.88 Million | $9.35 Million | — |